11.05.2015 • News

First Asian PA Plant Inaugurated at Shanghai

BASF has inaugurated a wholly owned 100,000 t/y plant for PA 6 and PA 6.6, sold under the "Ultramid" trademark, at Shanghai Chemical Industry Park (SCIP).

The new facility, the German group's first investment in polyamide in China, "shows our strong commitment to this market," said CEO Kurt Bock. The "innovative production setup" will allow BASF to supply its customers more quickly and with more flexibility, he added.

Albert Heuser, BASF's chief executive for Greater China, said the investment reflects management's confidence that demand for PA from the region's engineering plastics, fiber and film industries will continue to grow strongly.

Reports say caprolactam feedstock for the Chinese PA 6 plant will be supplied in part from BAFS's European production, with additional volumes to be procured locally, probably from an adjacent plant owned by US polyamide specialist Invista.

The US company is also building a PA plant at the site, earmarked for start-up later this year.

BASF is also a partner in an integrated world-scale isocyanates production at SCIP. Together with US polyurethanes specialist Huntsman, other partners in the Lianheng Isocyanate joint venture include several Chinese firms.

The joint venture recently received permission to doubling its MDI capacity to 480,000 t/y.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read